Alcon consensus stays stable, analysts focus on surgical growth and stock performance
25.06.2026 - 14:08:49 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 14:08.
Alcon Inc (CH0432492467) continues to draw a largely positive view from the sell-side community. MarketScreener data indicate that most analysts rate the NYSE-listed eye-care group as Buy or equivalent, while the average target price still sits above the current share price. MarketScreener consensus overview for Alcon
What recent analyst data show
According to MarketScreener, around two-thirds of the analysts covering Alcon currently recommend Buy, with the remainder mostly at Hold and very few at Sell, underscoring a broadly constructive stance on the stock. The consensus 12-month target price is clustered in the low to mid-80s US dollar range, implying moderate upside versus recent trading levels in the low 70s dollars. MarketScreener analyst breakdown and targets
In late April 2026, UBS reiterated its Buy rating on Alcon while fine-tuning its target price to reflect the company’s updated margin outlook and capital allocation plans, according to a Reuters round-up of analyst actions. UBS emphasized the company’s balanced growth profile between Surgical and Vision Care and highlighted the relatively defensive characteristics of ophthalmology demand even in a slower macroeconomic environment. Reuters broker research summary including UBS view on Alcon
Focus on surgical and vision-care momentum
Alcon’s first-quarter 2026 report showed mid-single-digit to high-single-digit year-on-year revenue growth, driven by strength in Surgical, where implantables and equipment continued to perform well, and steady demand in Vision Care, according to the company’s investor presentation. Management reiterated its full-year 2026 guidance for net sales growth in the high single digits and a further improvement in core operating margin, reflecting operating leverage in manufacturing and a more favorable product mix. Alcon Q1 2026 earnings presentation
Within Surgical, management highlighted continued uptake of premium intraocular lenses and growing demand for advanced cataract equipment platforms, which support both revenue expansion and margin accretion, according to the same deck. In Vision Care, daily disposable contact lenses and specialty lenses such as toric and multifocal products contributed to growth, offsetting more muted trends in some legacy lens categories.
All news and analysis on the Alcon shares
Track recent coverage, filings and price data around Alcon, from earnings details and guidance commentary to analyst opinion and valuation metrics.
The product behind the stock
One of Alcon’s flagship consumer products is the Dailies Total1 family of daily disposable contact lenses, which targets wearers looking for high comfort and oxygen permeability. The lenses use a water gradient material that delivers a very high water content at the surface, aimed at reducing dryness over long wearing periods.
Where the stock trades today
Alcon shares last traded on the New York Stock Exchange at 71.80 US dollars on 2026-06-25 at 11:30, according to exchange data.
Alcon at a glance
- Company: Alcon Inc
- ISIN: CH0432492467
- WKN: A2PHG9
- Ticker: ALC
- Trading venue: NYSE
- Price (as of 2026-06-25, 11:30): 71.80 USD
- Market cap: 35.2 billion USD (as of 2026-06-25)
- Sector / industry: Health Care - Medical Devices
- Index membership: S&P 500
- Next earnings date: 2026-08-06
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
